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In the majority of cases acute coronary syndromes (ACS) are caused by activation and
aggregation of platelets and subsequent thrombus formation leading to a decrease in coro-
nary artery blood ﬂow. Recent focus on the treatment of ACS has centered on reducing
the response of platelets to vascular injury as well as inhibiting ﬁbrin deposition. Novel
therapies include more effective P2Y12 receptor blockers thereby reducing inter-individual
variability, targeting the platelet thrombin receptor (protease activated receptor 1) as well
as directly inhibiting factor Xa or thrombin activity. In this review we discuss the clinical
data evaluating the effectiveness of these various new ACS treatment options.
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INTRODUCTION
Over the past two decades improvements in detection and man-
agement have reduced the incidence, the morbidity and the mor-
tality of acute coronary syndromes (ACS).Yet there are more
than 1 million events yearly in the United States alone and ACS
remains a leading cause of death in patients over 65 years of age
(Yeh et al., 2010). The term ACS denotes unstable angina, non-
ST-elevation myocardial infarction and ST-elevation myocardial
infarction and ischemic sudden death with the exact diagno-
sis dependent on the extent and severity of myocardial damage.
Necropsy studies have shown that 65% of sudden deaths resulting
from ACS occur from thin-cap ﬁbroatheromas; lesions charac-
terized as possessing a thin ﬁbrous cap (<65μm) overlying a
necrotic core. The remaining events are precipitated by super-
ﬁcial erosion of the ﬁbrous cap (Virmani et al., 2000). These
processes lead to platelet activation and aggregation, the forma-
tion of ﬁbrin rich thrombi, and the partial or total occlusion
of the coronary artery resulting in an ACS. With plaque rup-
ture or erosion there is release of tissue factor and exposure of
subendothelial collagen and von Willebrand factor (vWF). Cir-
culating platelets adhere to the exposed collagen and vWF and
undergo cytoskeletal rearrangement, generation of cyclooxyge-
nase I (COX-I) dependent thromboxane A2 (TXA2), and release
the contents of stored granules including adenosine diphosphate
(ADP). Interaction of TXA2 with the TXA2 receptor andADPwith
its receptor (P2Y12) initiates positive feedback activating addi-
tional platelets in a regionalmanner and promoting the expression
Abbreviations: ACS, acute coronary syndrome; AT-III, anti-thrombin-III; CABG,
coronary artery bypass grafting; COX-I, cyclooxygenase I; GpIIb–IIIa, glycopro-
tein IIb–IIIa; MI, myocardial infarction; NNT, number needed to treat; NS, non-
signiﬁcant; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous
coronary intervention; STEMI, ST-elevation myocardial infarction; TVR, target
vessel revascularization; TXA2, thromboxane A2; UA, unstable angina; vWF, von
Willebrand factor.
of the GpIIb–IIIa receptors. Coincident activation of factor X via
tissue factor results in thrombin generation, which elicits addi-
tional platelet degranulation and TXA2 release (Chackalamannil
and Xia, 2006) and catalyzing the formation of ﬁbrin,which serves
as the cross-link between GpIIb–IIIa receptors on neighboring
platelets (Figure 1).
Contemporary medical therapies are designed to promote
plaque stability, reduce platelet activation and aggregation,prevent
thrombus formation, and minimize myocardial oxygen demand.
New pharmacotherapies for ACS reﬂect efforts to improve efﬁcacy
and minimize complications of anti-platelet and anti-thrombotic
therapies by increasing target speciﬁcity and reducing inter-
individual variation in therapeutic response. In this review we will
describe recent advances in pharmacological therapy for ACS with
particular attention to platelet aggregation and thrombus forma-
tion. Agents targeting glycoprotein IIb/IIIa (Gp IIb/IIIa) receptors
will not be discussed.
ASPIRIN AND P2Y12 INHIBITORS
Aspirin irreversibly blocks COX-I, inhibiting generation of TXA2
and consequent platelet activation. In an early study assessing the
effect of aspirin in ACS, 1266 patients with unstable angina were
randomized to 324mg aspirin or placebo. Use of aspirin resulted
in a 51% reduction of either death orMI at 12weeks (p = 0.0002);
without an increase in bleedingwith sustained beneﬁt at 1 year fol-
low up (−43%, p = 0.008; Lewis et al., 1983). Subsequent smaller
studies corroborated this beneﬁt, and a meta-analysis of 15 ran-
domized trials including 135,000 patients identiﬁed a reduction
in the combined incidence of MI, stroke, or vascular death in
ACS patients treated with aspirin (−30± 4%, p< 0.0001). Subse-
quently, virtually every trial assessing ACS pharmacotherapy has
been performed on the background of aspirin therapy (Lewis
et al., 1983; ISIS Collaborative Group, 1988; Antiplatelet Trial-
ists’ Collaboration, 1994; Antithrombotic Trialists’ Collaboration,
2002).
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FIGURE 1 | Mechanism of acute coronary syndromes and targets of anti-platelet and anti-thrombotic agents.
The term “aspirin resistance” initially denoted patients who
suffered a vascular event while on aspirin therapy, yet speciﬁcally
refers to the inability of aspirin to sufﬁciently suppress TXA2 pro-
duction or platelet aggregation in vitro (Hennekens et al., 2004).
The determination of aspirin resistance is complicated by the
variable prevalence (6–26%) among studies depending on the lab-
oratory assay employed (Gum et al., 2001; Gasparyan et al., 2008).
Small prospective observational studies have identiﬁed increases
in the risk of MI (OR 2.0, CI 1.2–3.4, p = 0.006), cardiovascular
death (OR 3.5, CI 1.7–7.4, p< 0.001), and composite death,MI or
CVA (OR 3.12, CI 1.1–8.9, p = 0.03) in patients with high platelet
reactivity (HPR) on aspirin therapy (Eikelboom et al., 2002; Gum
et al., 2003; Gasparyan et al., 2008). As a result, the concept of
dual anti-platelet therapy (DAPT) emerged in order to reduce the
rate of vascular events among those with HPR on aspirin therapy,
and speciﬁcally to reduce the rate of reinfarction during and after
percutaneous coronary intervention (PCI).
Clopidogrel is a thienopyridine pro-drug (Table 1; Figure 2)
that requires cytochrome 2C19 (CYP2C19) biotransformation to
the active metabolite, an irreversible P2Y12 receptor inhibitor. In
a large prospective secondary prevention trial (n = 19,185), clopi-
dogrel alone compared to aspirin did not signiﬁcantly reduce
recurrent vascular events (stroke, MI, or vascular death) among
those with a history of myocardial infarction (−3.7%, p = 0.66),
and was associated with similar rates of bleeding (9.27 vs. 9.28%;
CAPRIE SteeringCommittee, 1996). However,when administered
together, clopidogrel and aspirin provide more complete and uni-
form suppression of platelet activation via dual pathways for the
lifespan of the platelet (average of 5–7 days;Moshfegh et al., 2000).
The CURE trial randomized 12,562 patients with UA or NSTEMI
to aspirin orDAPTwith aspirin and clopidogrel. Patients random-
ized toDAPThad a reduced incidence of composite cardiovascular
death, non-fatal MI, or stroke which was evident at 24 h (HR 0.66,
CI 0.51–0.86, p< 0.05) and persisted for at least 12months (HR
0.80, CI 0.72–0.90, p< 0.001). The event rate was driven primarily
by a reduction in non-fatal MI. Not unexpectedly, the combi-
nation of clopidogrel and aspirin was associated with increased
major bleeding rates (HR 1.38, CI 1.12–1.67, p = 0.001), although
there was no difference in life threatening bleeding. Among the
subgroup managed with a planned invasive strategy, the addi-
tion of clopidogrel was also associated with a signiﬁcant reduction
in composite cardiovascular death, non-fatal MI, or urgent tar-
get vessel revascularization at 30 days (HR 0.70, CI 0.50–0.97,
p = 0.03), with no difference inmajor bleeding (HR 1.13, CI 0.61–
2.1, p = 0.69; Mehta et al., 2001; Yusuf et al., 2001; Wright et al.,
2011).
Despite these population level beneﬁts, there is considerable
inter-individual variability in response to clopidogrel that at
least partially result from heterogeneity in CYP2C19 (Angiolillo
et al., 2007). The most common CYP2C19 variant is CYP2C19(2,
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Table 1 | Pharmacodynamics and pharmacokinetics of P2Y12 inhibitors in ACS.
Drug Drug class Half-life Metabolism Elimination Onset*
Clopidogrel Thienopyridine 6 h (pro-drug), 30min
(active metabolite)
Primarily CYP2C19 Renal and gastrointestinal 2 h
Prasugrel Thienopyridine 2–15 h (active metabolite) Serum esterase,
CYP3A4, and CYP2B6
Renal and gastrointestinal 30min
Ticagrelor Cyclo-pentyl-triazolo-pyrimidine 8–9 h Primarily CYP3A4 Hepatic and gastrointestinal 2–3 h
*Refers to loading dose administration.
FIGURE 2 | Structure of P2Y12 inhibitors.
which has an allelic frequency between 25 and 55% depending
on the ethnic population. Individuals with at least one copy of
CYP2C19(2 have reduced plasma concentrations of the active
clopidogrel metabolite and have reduced in vitro platelet respon-
siveness to clopidogrel (Kim et al., 2008; Kubica et al., 2011).
Moreover, the CYP2C19(2 variant has been associated with sig-
niﬁcant increases in the risk of vascular events in a number of
prospective studies and sub-studies of large ACS trials (reviewed
elsewhere; Angiolillo et al., 2007; Kubica et al., 2011).
The concept of “tailored” anti-platelet therapy has emerged
to describe an approach of providing stronger platelet inhibi-
tion to those patients with a lower risk of bleeding, in the early
phases of ACS when ischemic complications are the highest, or
in patients with residual HRP on DAPT (Wiviott et al., 2007;
Antman et al., 2008). The latter have been identiﬁed as a high
risk subset, with as much as a 6.7-fold increase in the 30-day risk
of composite death, myocardial infarction, or revascularization
in those undergoing PCI (Hochholzer et al., 2006). In patients
with HPR, clopidogrel dose escalation can incrementally reduce
platelet activity and decrease the incidence of HPR from 37 to
14% (p = 0.002; Gladding et al., 2008). However, whether HPR
should dictate subsequent therapy is unclear. The GRAVITAS trial
randomized patients that had undergone PCI with subsequent
identiﬁcation of HPR to placebo or an additional loading dose of
clopidogrel (600mg) and increased maintenance therapy (150mg
daily). There was no difference in the composite MI, cardiovas-
cular death, or stent thrombosis rate at 6months (HR 1.01, CI
0.58–1.76), despite a dose-associated reduction in HPR in those
randomized to higher-dose clopidogrel (38 vs. 60%, p< 0.001;
Price et al., 2011).
In order to overcome the impact of CYP2C19 heterogeneity
on platelet responsiveness novel ADP receptor antagonists have
been developed. Prasugrel is a thienopyridine structurally similar
to clopidogrel (Table 1; Figure 2) but less dependent on CYP2C19
biotransformation, and provides faster and more pronounced
platelet inhibition (Table 1; Mega et al., 2009b). In TRITON-TIMI
38,patients (n = 13,608)withACS andplannedPCIwere random-
ized to prasugrel (60mg loading dose followed by 10mg daily) or
clopidogrel (300mg loading dose followed by 75mg daily) for a
median of 14.5months. Prasugrel signiﬁcantly reduced the inci-
dence of non-fatal MI, (HR 0.76, CI 0.67–0.85, p< 0.001) driving
a signiﬁcant reduction in the composite cardiovascular outcome
that also included cardiovascular death and stroke (HR 0.81, CI
0.73–0.90, p< 0.001). This beneﬁt was associated with a signiﬁ-
cant increase in the risk of bleeding, including that classiﬁed as life
threatening (HR 1.5, CI 1.1–2.1, p = 0.01) and fatal (HR 4.2, CI
1.6–11.1, p = 0.002; Wiviott et al., 2007).
TRIGGER-PCI, designed to evaluate the efﬁcacy of prasugrel
in patients undergoing PCI with HPR on clopidogrel therapy, was
stopped after a preliminary analysis revealed low event rates and
an unlikely beneﬁt of prasugrel. The ongoing TRILOGY-ACS trial
is evaluating prasugrel in patients with ACS undergoing medical
management with HPR on clopidogrel therapy (Chin et al., 2010).
Unlike the thienopyridines, ticagrelor does not require con-
version to its active metabolite and provides reversible inhibition
of P2Y12 – features that theoretically confer less inter-individual
variation (Table 1; Figure 2). In preclinical studies ticagrelor was
not associated with greater bleeding than clopidogrel and pro-
vided more rapid and effective platelet inhibition (Husted et al.,
2006; Storey et al., 2007). The PLATO trial compared ticagrelor to
clopidogrel in ACS. In PLATO 18,624 patients admitted with ACS
were randomized to ticagrelor (180mg load, 90mg twice daily)
or clopidogrel (300 or 600mg load, 75mg daily). Ticagrelor was
associated with a signiﬁcant reduction in the composite endpoint
www.frontiersin.org October 2011 | Volume 2 | Article 61 | 3
Lilly andWilensky Emerging ACS therapies
of vascular death, myocardial infarction, or stroke (RR 0.84, CI
0.77–0.92, p = 0.0003) as well as all cause mortality (HR 0.78,
CI 0.69–0.89, p< 0.001) with no signiﬁcant increase in the rate of
compositemajor bleeding (HR1.04,CI 0.95–1.13,p = 0.43). There
was an increase in the intracranial bleeding rate (HR 1.87,CI 0.98–
3.58, p = 0.06; Wallentin et al., 2009) although subgroup analyses
demonstrated no increased bleeding rates in those identiﬁed as
“high risk” from TRITON-TIMI 38 including those>75 years old
(HR 1.04, CI 0.84–1.29, p = 1.0),<60 kg (HR 0.82, CI 0.60–1.12,
p = 0.12) and with known cerebrovascular disease (HR 0.99, CI
0.71–1.37, p = 0.77; Wallentin et al., 2009).
Two novel anti-platelet agents have recently entered clinical tri-
als forACS: atopaxar and vorapaxar. Both are synthetic antagonists
of the platelet thrombin receptor (protease activated receptor 1),
and have the potential advantage of impeding platelet aggregation
during rapid thrombin formation such as ACS (Morrow et al.,
2009). In phase II trials with atopaxar, Japanese patients with
ACS (n = 241) were randomized to 50–200mg daily or placebo
in addition to standard therapy (>96% aspirin, >89% clopido-
grel) for 12weeks. The bleeding rate was similar among all doses
of atopaxar and placebo (5.0 vs. 6.6%, NS). However, there was
an increased frequency of liver enzyme elevation among patients
randomized to the 100 (6.2%) and 200mg (14.8%) doses (Goto
et al., 2010b). In phase II trial of vorapaxar, patients (n = 1030)
with stable CAD undergoing non-urgent PCI receiving vorapaxar
(10–40mg load, with 0.5–2.5mg daily) for 60 days had bleeding
rates that were comparable to placebo (41% grouped vorapaxar
vs. 35% placebo, NS). Moreover, those randomized to vorapaxar
had non-signiﬁcant reductions composite death or myocardial
infarction (5% grouped vorapaxar vs. 7% placebo, NS; Becker
et al., 2009). Phase III trials including more than 40,000 patients
with ACS (TRACER) or a history of vascular disease (TrA2P-
TIMI 50) are underway (Morrow et al., 2009; Van De Werf,
2010).
ANTI-THROMBOTIC AGENTS
HEPARINS
The heparins complex with anti-thrombin-III (AT-III) and accel-
erate AT-III mediated inhibition of factor Xa and thrombin
(Figure 1). Unfractionated heparin (UFH) represents the
cornerstone of anti-thrombotic therapy in ACS, but has a num-
ber of limitations. UFH poorly inhibits clot-associated thrombin
activity resulting in persistent proaggregant and procoagulant
thombin activity at the site of arterial thrombosis. Additional con-
cerns with UFH include heparin-induced thrombocytopenia and
thrombosis (HITT), the necessity of frequent monitoring, and
platelet-activating effects at therapeutic doses (Xiao and Theroux,
1998).
Low molecular weight heparin (LMWH) provides greater fac-
tor Xa inhibition, a reduced incidence of HITT, and more pre-
dictable bioavailability and elimination characteristics than UFH.
A number of trials comparing enoxaparin to UFH demonstrated
comparable or superior efﬁcacy with regard to ischemic ACS
endpoints yet small increases in bleeding with enoxaparin, par-
ticularly when invasive strategies were employed (Antman et al.,
1999, 2006; Goodman et al., 2000;Wallentin et al., 2003; Ferguson
et al., 2004). A meta-analysis encompassing 12 randomized trials
(n = 49,088) comparing enoxaparin to UFH in ACS concluded
that there were signiﬁcant reductions in the incidence of MI (HR
0.75, CI 0.65–0.86, p< 0.001) at 30 days, with an increase inmajor
bleeding (HR 1.25,CI 1.04–1.50,p = 0.02). The net clinical beneﬁt
endpoint (death, MI, or major bleeding), approached signiﬁcance
at 30 days (HR 0.90, CI 0.76–1.00, p = 0.051; Murphy et al., 2007).
Other LMWHs have also been evaluated in ACS but are in less
frequent clinical use due to inferior clinical results (tinzaparin,
dalteparin) or increased bleeding (nadroparin; Klein et al., 1997;
Michalis et al., 2003; Katsouras et al., 2005; Table 2). As LMWHs
are cleared renally and given that monitoring tests are less reliably
available,UFH is preferable in those with advanced chronic kidney
disease.
DIRECT FACTOR XA INHIBITORS
Direct factor Xa inhibitors block the coagulation cascade at an
earlier step and are able to inhibit free and clot-associated factor
Xa. Currently there is one direct factor Xa inhibitor FDA approved
for use in ACS (fondaparinux) with three others in preclinical
trials (apixaban, rivaroxaban,otamixaban). Fondaparinux is a syn-
thetic pentasaccharide that mimics the AT-III binding portion
of heparin and enhancing the anti-factor Xa activity >300-fold
(Table 3; Figure 3). It is administered parenterally, eliminated
Table 2 | Low molecular weight heparins in ACS.
ESSENCE In 3171 patients with UA or NSTEMI, enoxaparin reduced composite death, MI, recurrent angina at 30 days (19.8 vs. 23.3%, p =0.016) and
12months (32.0 vs. 35.7%, p =0.022) with no change in major bleeding (6.5 vs. 7.0%; Goodman et al., 2000)
TIMI 11B In 3910 patients with UA or non-Q wave MI, enoxaparin reduced composite death, MI, or urgent revascularization at 8 days (OR 0.83, CI
0.69–1.0, p =0.048) with no increase in major bleeding (Antman et al., 1999)
SYNERGY In 10 027 patients with NSTEMI and planned early invasive strategy, enoxaparin did not reduce composite death or non-fatal MI at 1 (14.0
vs. 14.5%, NS) or 6months (17.6 vs. 17.8%, NS); increased major bleeding (9.1 vs. 7.6%; Ferguson et al., 2004)
FRISC In 1506 patients with NSTEMI randomized to placebo or dalteparin. Dalteparin reduced composite death and MI at 6 days (HR 0.37, CI
0.20–0.68, p =0.001), with no change in major or minor bleeding (FRISC Study Group, 1996)
FRIC In 1482 patients with ACS dalteparin compared to UFH did not reduce composite death, MI, angina recurrence at 6 days (HR 1.18, CI
0.84–1.66, p =0.33), there was no difference in major bleeding (1.0 vs. 1.1%; Klein et al., 1997)
FRAXIS In 3468 patients with ACS nadroparin compared to UFH resulted in similar rates of composite cardiac death, MI, refractory angina, or
recurrence of angina at day 14 (18.1 vs. 20.1%, NS) with increased major bleeding (3.5 vs. 1.6%, p<0.001; FRAX. I. S. Study Group, 1999)
EVET In 438 patients with ACS, enoxaparin compared to tinzaparin reduced composite recurrent angina, MI, or death at 30 days (17.7 vs. 28.0%,
p =0.012) with no difference in major bleeding (<2 patients per group, NS; Michalis et al., 2003)
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Table 3 | Pharmacodynamics and pharmacokinetics of anti-coagulants in ACS.
Drug Mechanism Half-life Metabolism Elimination Onset Notes
UFH AT-III mediated factor
Xa and thrombin
inhibitor
IV or SC 1–2 h Hepatic Extra-renal at
therapeutic doses
Immediate
(IV), 30min
(SC)
Inactive on clot-associated
thrombin
Unpredictable bioavailability
Enoxaparin AT-III mediated factor
Xa and thrombin
inhibitor
SC 5–7 h Hepatic Renal 3–5 h Inactive on clot-associated
thrombin
More factor Xa selectivity
Fondaparinux Indirect factor Xa
inhibitor
SC 17–21 h Excreted largely as
unchanged drug
Renal 2–3 h Inactive on clot-associated
thrombin
Not for use in advancedCKD
Rivaroxaban Direct factor Xa
inhibitor
Oral 9–13 h Hepatic Renal and
gastrointestinal
2–4 h Phase III trials underway
Apixaban (−) Factor Xa (direct) Oral 12 h Renal and biliary 3 h Phase III trials underway
Otamixaban (−) Factor Xa (direct) IV 2–3 h Biliary Immediate Phase III trials underway
Bivalirudin Direct thrombin
inhibitor, reversible
IV 25min Plasma proteases Renal Immediate Inhibits clot-associated
thrombin
Dabigatran Direct thrombin
inhibitor, reversible
Oral 12–17 h Hepatic and plasma Renal and
gastrointestinal
1 h Pro-drug, low bioavailability
FIGURE 3 | Structure of factor Xa and direct thrombin inhibitors.
renally, with little inter-individual variability and no need for
routine monitoring.
The utility of fondaparinux inACSwas ﬁrst assessed in the dose
ﬁnding PENTALYSE trial. STEMI patients (n = 333) undergoing
thrombolysis were randomized to 48–72 h of UFH or one of ﬁve
fondaparinux doses for 5–7 days. Patients receiving fondaparinux
had lower 30 day revascularization rates (39 vs. 51%, p = 0.054)
with a similar major bleeding risk (7.1 vs. 7.1%; Coussement et al.,
2001). In the PENTUA trial patients with UA or NSTEMI were
randomized to one of four doses of fondaparinux or enoxaparin
for a period for 3–7 days after identiﬁcation of ACS. Fondaparinux
at the lowest dose (2.5mg daily) provided a non-signiﬁcant reduc-
tion in composite death, MI, or recurrent ischemia at 9 days (27.9
vs. 35.7% in the enoxaparin group, NS) with no major bleed-
ing and comparable rates of minor bleeding (3.9 vs. 4.8%, NS;
Simoons et al., 2004).
In the largest ACS trial to date (OASIS-5), over 20,000 patients
with UA or NSTEMI were randomized to fondaparinux (2.5mg
daily) or enoxaparin (1mg/kg twice daily) for a mean of 6 days.
There was no difference in the incidence of composite death, non-
fatal MI, or refractory ischemia (HR 1.01, CI 0.9–1.13) between
fondaparinux and enoxaparin. However, major bleeding was
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signiﬁcantly decreased with fondaparinux at 9 days (HR 0.52, CI
0.44–0.61, p< 0.001) and all cause mortality was lower at 30 (HR
0.83, CI 0.71–0.91, p = 0.02) and 180 days (HR 0.89, CI 0.80–1.0,
p = 0.05; Yusuf et al., 2006a). OASIS-6 was designed to determine
whether fondaparinux was superior to UFH in STEMI patients
who underwent mechanical revascularization or pharmacological
thrombolysis (Yusuf et al., 2006b). Patients were randomized to
fondaparinux (2.5mg daily for 8 days or until discharge) or UFH
(for 24–48 h); those in which UFH was deemed unnecessary (pri-
marily following streptokinase administration) were randomized
to fondaparinux or placebo. Fondaparinux was associated with
a signiﬁcant reduction in the incidence of the death or reinfarc-
tion at 30 days (HR 0.86, CI 0.77–0.96, p = 0.008); an effect that
persisted to 6months. There was no difference in bleeding rates.
The reductions in the composite cardiovascular outcomes
with fondaparinux in the OASIS trials were restricted to those
who underwent conservative management or thrombolysis, while
the beneﬁt of fondaparinux was not apparent in patients who
underwent primary PCI. Furthermore, fondaparinux was asso-
ciated with increased catheter related thrombi, prompting the
subsequent use of procedural intravenous fondaparinux. In the
event patients managed under a conservative strategy proceed to
PCI on fondaparinux, current guidelines recommend a transition
to an agent with anti-thrombin activity.
Otamixaban is a synthetic parenteral factor Xa inhibitor with
a rapid onset of action and biliary clearance (Table 3; Figure 3).
Phase II trials in patients undergoing planned PCI and those with
high risk ACS are promising. Compared to UFH with eptiﬁbatide,
otamixaban has been associated with reductions in the rate of
death or myocardial infarction at 7 days (HR 0.52, CI 0.28–0.98
with 0.105mg/kg/h) with comparable rates of bleeding (3.1 vs.
2.7%; Cohen et al., 2007; Sabatine et al., 2009). The ongoing TAO
trial is powered for ischemic endpoints and is evaluating otamix-
aban vs. UFH and eptiﬁbatide in patients with ACS undergoing a
planned invasive strategy.
Two orally administered synthetic factor Xa inhibitors are
presently in phase III trials: rivaroxaban and apixaban (Table 3;
Figure 3; Rothberg et al., 2005). Rivaroxaban is an orally admin-
istered factor Xa inhibitor, with high bioavailability and a rapid
onset of action. ATLAS TIMI 46 was a phase II trial in which
patients admitted with ACS and subsequently stabilized were ran-
domized to placebo or escalating doses of rivaroxaban. Compared
to placebo, rivaroxaban was associated with a non-signiﬁcant
decrease in the primary efﬁcacy endpoint (death, MI, stroke,
recurrent ischemia requiring revascularization) at the lowest dose
(5mg twice daily; HR 0.60, CI 0.29–1.25) with dose-dependent
increases in bleeding (HR 1.71,CI 0.76–3.85 with 5mg twice daily;
Mega et al., 2009a). A phase III trial of 2.5 and 5mg twice daily
rivaroxaban is presently underway (ATLAS 2 TIMI 51).
Phase II trials with apixaban have yielded similar results
(Alexander et al., 2009). The phase III APRAISE-2 trial, patients
with ACS (n = 7832) were randomized to placebo or 5mg twice
daily of apixaban in addition to standard DAPT. At a mean follow
up of 241 days, apixaban therapy was not associated with a reduc-
tion in composite cardiovascular death, MI, or stroke (HR 0.97,
CI 0.8–1.1, p = 0.51) while resulting in increased major bleeding
(HR 2.59, CI 1.5–4.5, p = 0.001; Alexander et al., 2011).
DIRECT THROMBIN INHIBITORS
Unlike the heparins, direct thrombin inhibitors are independent
of AT-III, reduce the formation of ﬁbrin monomers and abro-
gate the direct platelet-activating effects of thrombin on platelets.
Direct thrombin inhibitors are also active on clot-bound throm-
bin, providing a regional speciﬁcity that heparins lack. Bivalirudin
is approved for ACS, while dabigatran is currently in clinical trials.
Bivalirudin is a synthetic and reversible direct thrombin
inhibitor (Table 3; Figure 3; Sibbing et al., 2008). Initially evalu-
ated in patients with unstable or post-infarction angina undergo-
ing planned angioplasty (n = 4098), bivalirudin therapy (1mg/kg
bolus then 2.5mg/kg/h) reduced composite death, myocardial
infarction, and repeat revascularization at 7 days (HR 0.78, CI
0.62–0.99, p = 0.039) with a reduced risk of bleeding (HR 0.34, CI
0.26–0.45, p< 0.001; Bittl et al., 2001). Subsequently REPLACE-2
was designed to compare the combination of UFH and GpIIb–
IIIa inhibition to bivalirudin (0.75mg/kg bolus, followed by
1.75mg/kg/h for procedure duration) with provisional GpIIb–IIIa
inhibition (if procedural complications dictated) in the setting of
urgent or elective PCI (n = 6010). Bivalirudin was associated with
a similar incidence in composite rate of death, myocardial infarc-
tion, and urgent revascularization (7.6 vs. 7.1%, p = 0.40), with
a highly signiﬁcant decrease in bleeding (2.4 vs. 4.1%, p< 0.001;
Lincoff et al., 2003).
These trials, together with CACHET (Bittl et al., 2001; Lincoff
et al., 2002) supported the use of bivalirudin during PCI, although
patients with high risk ACS had been excluded. The ACUITY trial
randomized nearly 14,000 patients with high risk UA or NSTEMI
to (1) UFH or LMWH plus GpIIb–IIIa inhibitor, (2) bivalirudin
plus GpIIb–IIIa inhibitor, or (3) bivalirudin alone. Bivalirudin
alone conferred similar efﬁcacy with respect to the primary car-
diovascular endpoint (death, MI, urgent revascularization; HR
1.08, CI 0.93–1.24, p< 0.001 for non-inferiority) with signiﬁ-
cantly reduced major bleeding (HR 0.53, CI 0.43–0.65, p< 0.001)
compared to the heparin group (Stone et al., 2006).
Finally, the HORIZONS-AMI trial was designed to specif-
ically address whether or not bivalirudin offered a superior
risk–beneﬁt proﬁle in patients with STEMI undergoing planned
PCI. Patients with STEMI (n = 3602) within the preceding 12 h
were randomized to heparin and GpIIb–IIIa or bivalirudin
monotherapy (0.75mg/kg bolus, then 1.75mg/kg/h), with anti-
thrombin therapies generally discontinued at PCI completion.
Bivalirudin was associated with a reduced incidence of the com-
posite outcome (death, reinfarction, revascularization, stroke, or
major bleeding) at 30 days, driven primarily by decreased rates of
major bleeding (HR 0.60, CI 0.46–0.77, p< 0.001), and death.
All cause mortality at 30 days was signiﬁcantly lower in the
bivalirudin group (HR 0.66, CI 0.44–1.0, p = 0.047), an effect
maintained at 3 year follow up. The bleeding and survival ben-
eﬁts of bivalirudin were evident in those that had received heparin
therapy prior to randomization, and at all stages of renal dis-
ease – subgroups in where LMWH have proven less safe (Fer-
guson et al., 2004; Cohen et al., 2006), or are unadvised due to
primary renal elimination and concern for bleeding risk (Rob-
son, 2000; Sun et al., 2007). Whether or not early initiation
of bivalirudin provides incremental beneﬁt is the focus of the
ongoing EUROMAX trial, in which patients with STEMI and
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Table 4 | Recent trials of ACS therapies.
CLOPIDOGREL
GRAVITAS
Patients that underwent DES implantation with HPR on clopidogrel therapy were randomized to standard (75mg daily) or high dose clopidogrel (150mg
daily). Primary endpoint was CV death, NFMI, deﬁnite, or probable stent thrombosis
High dose clopidogrel did not reduce composite primary outcome (Price et al., 2011)
PRASUGREL
TRITON-TIMI 38 sub-studies
Prasugrel conferred a reduction in primary endpoint in patients not undergoing stent implantation (HR 0.82, CI 0.53–1.25, p=0.27), with an increase in
non-CABG related major bleeding (0 vs. 5 events; Pride et al., 2009)
Prasugrel reduced incidence of primary endpoint in patients in patients that did (HR 0.76, CI 0.64–0.90) and did not (HR 0.78, CI 0.63–0.97) receive
GpIIb–IIIa inhibitor therapy (O’donoghue et al., 2009)
Prasugrel resulted in greater platelet inhibition than clopidogrel in patients admitted with ACS both at 1–2 h and at 30 days (Michelson et al., 2009)
Prasugrel reduced incidence of primary endpoint at 30 days (HR 0.68, CI 0.54–0.87) and 15months (HR 0.79, CI 0.65–0.97) in patients with STEMI;
increased major post-CABG bleeding (HR 6.53, CI 1.78–23.94; Montalescot et al., 2009)
SWAP trial
Phase II trial in patients after ACS on clopidogrel 75 daily and then randomized to continued clopidogrel, prasugrel 10mg daily, or prasugrel 60mg once
then 10mg daily
Compared to maintenance clopidogrel, prasugrel therapy was associated with greater platelet inhibition as early as 2 h (60mg load then 10mg daily) and
6 days (10mg daily) that persisted through 14 days (Angiolillo et al., 2010)
TICAGRELOR
PLATO sub-studies
Ticagrelor reduced primary endpoint (HR 0.84, CI 0.75–0.94), no difference in major bleeding (HR 0.99, CI 0.89–1.10) in those undergoing invasive strategy
(Cannon et al., 2010)
In STEMI and planned reperfusion, ticagrelor reduced the incidence of primary endpoint (HR 0.87, CI 0.75–1.01), and all cause mortality (HR 0.82, CI
0.67–1.0), with no difference in major bleeding (Steg et al., 2010a)
In those with CKD ticagrelor reduced the incidence of primary endpoint (HR 0.77, CI 0.65–0.90), and all cause mortality (HR 0.72, CI 0.58–0.89; James
et al., 2010)
BIVALRUDIN
HORIZONS-AMI
Acute stent thrombosis more frequent in patients randomized to bivalirudin (HR 4.43, CI 1.52–12.92; Dangas et al., 2011)
Bivalirudin provided comparable reductions in primary endpoints irrespective of the necessity for transfer to PCI-able facility (Wohrle et al., 2010)
In high risk patients bivalirudin use reduced 1 year mortality (8.4 vs. 15.9%, p =0.014) and reinfarction (3.6 vs. 7.9%, p =0.042; Parodi et al., 2010)
Bivalirudin provided comparable reductions in net adverse clinical events in those receiving 300mg (12.3 vs. 15.2%, p =0.15) and the 600mg (7.3 vs.
10.4%, p =0.01) clopidogrel prior to PCI (Dangas et al., 2009)
Bivalirudin monotherapy reduced net adverse cardiac events (HR 0.83, CI 0.71–0.97, p =0.02), and all cause mortality (HR 0.71, CI 0.51–0.98) at 12months
(Mehran et al., 2009a)
ACUITY sub-studies
Patients (n=14,000) with UA/NSTEMI randomized to heparin+GpIIb–IIIa inhibitor, bivalirudin+GpIIb–IIIa inhibitor, or bivalirudin alone. Primary endpoints:
(1) death, NFMI, unplanned revascularization, (2) major bleeding, (3) ischemia and major bleeding
In those with CKD, bivalirudin reduced major bleeding (RR 0.64, CI 45–0.89, p =0.008) with comparable composite ischemia effect (RR 1.18, CI 0.88–1.57,
p =0.27; Mehran et al., 2009b)
Bivalirudin was associated with reduced access-related major bleeding in patients that underwent femoral (3.0 vs. 5.8%, p<0.0001), but not radial access
(4.2 vs. 2.2%, p =0.19; Hamon et al., 2009)
Among the elderly (>75 years old) bivalirudin resulted in comparable composite ischemia (11.7 vs. 9.6%, NS), with fewer major bleeds (5.8 vs. 10.1%,
p<0.05, NNT 16; Lopes et al., 2009)
Bivalirudin was associated with similar rates of early (<30day) stent thrombosis (1.4 vs. 1.1%, p =0.37; Aoki et al., 2009)
Bivalirudin was associated with less acquired thrombocytopenia (HR 0.75, CI 0.61–0.93; Caixeta et al., 2011)
No relationship between the time to anti-thrombin initiation and ischemic outcomes in patients admitted with ACS. Thirty-day bleeding risk increased as
time to anti-thrombin initiation increased (OR 1.44, CI 1.15–1.80; Diercks et al., 2011)
Among patients undergoing PCI to vein grafts, there was a comparable incidence of major cardiac events and major bleeding with bivalirudin monotherapy
(Kumar et al., 2010)
Among patients referred for medical therapy after angiography (32.4%), bivalirudin resulted in less major bleeding (4.4 vs. 2.5%, p =0.005) with no
difference in composite ischemia endpoint at 30 days (HR 0.87, CI 0.55–1.37) or 1 year (HR 1.01, CI 0.76–1.34; Goto et al., 2010a)
(Continued)
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Table 4 | Continued
CLOPIDOGREL
Retrospective registry study of retroperitoneal hemorrhage after PCI in Michigan between 2002 and 2007
Bivalirudin use was associated with signiﬁcantly fewer retroperitoneal hemorrhages (OR 0.51, CI 0.34–0.76, p<0.001; Trimarchi et al., 2010)
ACTION registry sub-study
Retrospective study of anti-coagulant strategy from January to December 2007 in patients with NSTEMI undergoing PCI (n=11,085)
Compared to reference heparin+GpIIb–IIIa (64%), bivalirudin alone (10.5%) was associated with less major bleeding (OR 0.48, CI 0.39–0.60) and lower
in-hospital mortality (OR 0.39, CI 0.21–0.71; Lopes et al., 2010)
FONDAPARINUX
OASIS-6 sub-study
Patients (n=12,092) with STEMI were randomized to fondaparinux (2.5mg daily) or UFH. Primary endpoint was death, MI, or refractory ischemia at
30 days
There were comparable reductions in the incidence composite death or MI, as well as the incidence of major bleeding across age tertiles (Van ReesVellinga
et al., 2010)
FUTURE/OASIS-8
Standard (85U/kg UFH bolus and ACT 300–350 or 60U/kg and ACT 250–300 if GpIIb–IIIa) or low-dose (50U/kg UFH bolus without ACT adjustment) heparin
regimen during PCI in patients with NSTEMI that received initial fondaparinux
No difference between UFH regimens on composite major and minor bleeds (OR 0.80, CI 0.54–1.12, p =0.27) but a trend toward increased composite
death, MI, TVR (OR 1.58, CI 0.98–2.53, p =0.06; Steg et al., 2010b)
French registry of anti-coagulant use in the setting of ACS between January and December 2007
Adjusted 30 day mortality rates were higher in patients treated with UFH compared to fondaparinux as the initial (HR 3.1, CI 1.3–7.4), and ﬁnal anti-coagulant
(HR 3.1, CI 1.3–7.3; Schiele et al., 2010)
OASIS-5
Fondaparinux reduced major bleeding in patients receiving discretionary GpIIb–IIIa inhibition (HR 0.60, CI 0.46–0.78) or pre-procedural thienopyridines (HR
0.62, CI 0.52–0.73; Jolly et al., 2009)
Fondaparinux was associated with a cost savings of $547 (CI $207–$924) per patient compared to enoxaparin therapy at 6months (Sculpher et al., 2009)
Fondaparinux was associated with a similar incidence primary endpoint (NS at all strata), and signiﬁcantly lower risk of major bleeding with in patients
with low (HR 0.55, CI 0.39–0.77), medium (HR 0.53, CI 0.40–0.70), and high (HR 0.50, CI 0.38–0.64) risk of bleeding (Joyner et al., 2009)
RIVAROXABAN
ATLAS ACSTIMI 46
Patients with stabilized ACS (n=3,491) randomized to rivaroxaban or placebo and treated for 6months. Primary safety endpoint: clinically signiﬁcant
bleeding; Primary efﬁcacy endpoint: death, NFMI, stroke, or recurrent ischemia
At 5mg twice daily, rivaroxabanwas associatedwith increased bleeding (HR 1.71, CI 0.76–3.85), and a non-signiﬁcant reduction in primary efﬁcacy endpoint
(HR 0.60, CI 0.29–1.25; Mega et al., 2009a)
APIXABAN
APPRAISE
Patients with stabilized ACS (n=1,715) randomized to one of four doses of apixaban or placebo. Primary outcome was major or clinically relevant bleeding.
Secondary outcome was CV death, MI, severe recurrent ischemia, or ischemic stroke
At the lowest dose studied, apixaban (2.5mg twice daily) was associated with non-signiﬁcant increases in bleeding (HR 1.8, CI 0.91–2.48, p =0.09), and
non-signiﬁcant decreases in composite CV death, MI, recurrent ischemia, and stroke (HR 0.73, CI 0.44–1.2, p =0.21; Alexander et al., 2009)
OTAMIXABAN
SEPIA-ACSTIMI 42
Patients with NSTEMI (n=3,241) were randomized to one of ﬁve otamixaban doses or UFH plus eptiﬁbatide. Primary efﬁcacy endpoint: death, MI, urgent
revascularization, or bailout GpIIb–IIIa inhibitor use. Primary safety endpoint: CABG unrelated bleeding
Otamixaban at an intermediate dose (0.105mg/kg/h) was associated with reduced incidence of primary efﬁcacy endpoint (R 0.61, CI 0.36–1.02), with a
non-signiﬁcant increase in bleeding (3.1 vs. 2.7%; Sabatine et al., 2009)
planned PCI will be provided bivalirudin or UFH by emergency
medical personnel.
Dabigatran is a synthetic, competitive, and reversible direct
thrombin inhibitor with good oral bioavailability (Table 3;
Figure 3). Recently approved for the prevention of stroke in
patients with atrial ﬁbrillation (Connolly et al., 2009), dabiga-
tran is undergoing evaluation in ACS. In a phase II dose ﬁnding
study, patients with ACS and at high risk for additional events
were randomized to dabigatran twice daily or placebo a median
of 7 days after the event and treated for 6months. Preliminary
ﬁndings demonstrated no difference in rate of composite cardio-
vascular death,non-fatalmyocardial infarction,or stroke (3.8%on
placebo, 4.6% 50mg, 3.5% 150mg) or the risk of bleeding (0.54%
on placebo, 0.81% 50mg, 1.73% 150mg), although there was a
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trend toward increased minor bleeding at every dose (Oldgren
et al., 2009).
CONCLUSION
Platelet aggregation and thrombus formation comprise the inter-
mediary events between plaque instability and MI, and phar-
macological inhibition of these events has led to substantial
reductions in ischemic complications andmortality. Newer agents
are characterized by more predictable pharmacokinetics, reduced
inter-individual response variability, and activity at the site of
coronary occlusion. Recently approved agents (bivalirudin, fon-
daparinux, prasugrel, ticagrelor) have improved outcomes in clin-
ical trials by more effectively balancing the anti-ischemic bene-
ﬁts and bleeding risks during ACS. Identifying the timing and
setting of anti-platelet and anti-coagulant initiation, and the
subgroups in which one agent provides a comparably favor-
able risk-beneﬁt proﬁle remains an area of active investigation
(Table 4).
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